Skip to main content

Table 2 Genes under-expressed in patients with JRA

From: Evidence for chronic, peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis

GenBank accession no. Symbol Description Avg. control Avg. patients Ratio C/P
NM_001145 ANG Angiogenin, ribonuclease, RNase A family, 5 18.8 6.1 3.1
NM_000041 APOE Apolipoprotein E 16.9 7.2 2.3
NM_002983 CCL3 chemokine (C-C motif) ligand 3 166.7 7.4 22.4
D90145 CCL3L1 chemokine (C-C motif) ligand 3-like 1 197.7 21.4 9.2
NM_002984 CCL4 chemokine (C-C motif) ligand 4 221.7 22.2 10.0
NM_002985 CCL5 chemokine (C-C motif) ligand 5 38.5 8.3 4.7
NM_001781 CD69 CD69 antigen (p60, early T-cell activation antigen) 23.5 4.5 5.2
NM_004233 CD83 CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) 24.3 0.1 365.9
NM_031226 CYP19A1 cytochrome P450, family 19, subfamily A, polypeptide 1 25.8 9.2 2.8
NM_004408 DNM1 Dynamin 1 13.6 4.1 3.3
NM_004418 DUSP2 Dual specificity phosphatase 2 54.1 7.8 6.9
NM_000114 EDN3 Endothelin 3 36.7 11.8 3.1
NM_001961 EEF2 Eukaryotic translation elongation factor 2 114.1 29.1 3.9
NM_005252 FOS V-fos FBJ murine osteosarcoma viral oncogene homolog 483.5 100.4 4.8
NM_006732 FOSB FBJ murine osteosarcoma viral oncogene homolog B 89.6 11.7 7.7
NM_015675 GADD45B Growth arrest and DNA-damage-inducible, beta 87.5 19.3 4.5
NM_012483 GNLY Granulysin 47.5 2.5 19.2
NM_006144 GZMA Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) 15.3 4.5 3.4
NM_019111 HLA-DRA Major histocompatibility complex, class II, DR alpha 226.5 33.9 6.7
NM_006895 HNMT Histamine N-methyltransferase 13.4 4.4 3.1
NM_031157 HNRPA1 Heterogeneous nuclear ribonucleoprotein A1 31.8 8.8 3.6
NM_014365 HSPB8 heat shock 22-kDa protein 8 23.8 7.0 3.4
NM_000576 IL1B Interleukin 1, beta 169.0 22.4 7.5
AK055991 LAMR1 Laminin receptor 1 (67 kDa, ribosomal protein SA) 35.3 14.2 2.5
NM_002305 LGALS1 Lectin, galactoside-binding, soluble, 1 (galectin 1) 15.5 4.3 3.6
X60188 MAPK3 Mitogen-activated protein kinase 3 228.5 81.3 2.8
NM_020529 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 705.4 56.0 12.6
NM_002135 NR4A1 Nuclear receptor subfamily 4, group A, member 1 46.0 15.4 3.0
NM_006186 NR4A2 Nuclear receptor subfamily 4, group A, member 2 35.7 9.5 3.8
U12767 NR4A3 Nuclear receptor subfamily 4, group A, member 3 18.3 4.4 4.2
BC011589 OSM Oncostatin M 19.8 5.3 3.8
NM_002659 PLAUR Plasminogen activator, urokinase receptor 23.8 4.8 4.9
NM_000311 PRNP Prion protein (p27-30) 15.0 5.1 3.0
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 174.9 30.4 5.8
NM_002823 PTMA Prothymosin, alpha (gene sequence 28) 169.0 56.0 3.0
NM_000994 RPL32 Ribosomal protein L32 174.4 58.6 3.0
NM_002966 S100A10 S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide [p11]) 33.9 9.2 3.7
NM_003745 SOCS1 suppressor of cytokine signaling 1, SSI-1 23.1 8.2 2.8
NM_032298 SYT3 synaptotagmin III, DKFZp761O132 30.2 11.4 2.7
NM_003246 THBS1 Thrombospondin 1 33.7 11.1 3.0
NM_006290 TNFAIP3 Tumour necrosis factor, alpha-induced protein 3 112.1 24.9 4.5
NM_003407 ZFP36 Zinc finger protein 36, C3H type, homolog (mouse) 177.8 51.5 3.5
  1. Avg. control, average (normalised) intensity in controls; Avg. patients, average (normalised) intensity in patients; Ratio C/P, fold difference between controls and patients.